Pimecrolimus
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00337 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 19 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | seborrheic dermatitis | KG + DL |
| 2 | dermatitis | KG + DL |
| 3 | exanthem (disease) | KG + DL |
| 4 | acrodermatitis chronica atrophicans | KG + DL |
| 5 | parapsoriasis | KG + DL |
| 6 | acne keloid | KG + DL |
| 7 | neonatal dermatomyositis | KG + DL |
| 8 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
| 9 | hydroa vacciniforme, familial | KG + DL |
| 10 | acute lichenoid pityriasis | KG + DL |
| 11 | amyopathic dermatomyositis | KG + DL |
| 12 | bronchitis | KG + DL |
| 13 | psoriasis | KG + DL |
| 14 | pityriasis lichenoides | KG + DL |
| 15 | seborrheic keratosis | KG + DL |
| 16 | vulvar inverted follicular keratosis | KG + DL |
| 17 | pityriasis simplex | KG + DL |
| 18 | pustulosis palmaris et plantaris | KG + DL |
| 19 | 2-hydroxyethyl methacrylate sensitization | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.